Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.
Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S. Davey RT, et al. Among authors: saag ms. J Interferon Cytokine Res. 2008 Feb;28(2):89-100. doi: 10.1089/jir.2007.0064. J Interferon Cytokine Res. 2008. PMID: 18279104 Clinical Trial.
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Carpenter CC, et al. Among authors: saag ms. JAMA. 2000 Jan 19;283(3):381-90. doi: 10.1001/jama.283.3.381. JAMA. 2000. PMID: 10647802 Review.
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A. Kilby JM, et al. Among authors: saag ms. AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):685-93. doi: 10.1089/088922202760072294. AIDS Res Hum Retroviruses. 2002. PMID: 12167274 Clinical Trial.
Duration of highly active antiretroviral therapy regimens.
Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, Acosta EP, Taylor KH, Carter J, Saag MS. Chen RY, et al. Among authors: saag ms. Clin Infect Dis. 2003 Sep 1;37(5):714-22. doi: 10.1086/377271. Epub 2003 Aug 13. Clin Infect Dis. 2003. PMID: 12942406
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel. Hammer SM, et al. Among authors: saag ms. JAMA. 2006 Aug 16;296(7):827-43. doi: 10.1001/jama.296.7.827. JAMA. 2006. PMID: 16905788
517 results